{
    "root": "7f32151f-3c34-4818-890b-34f22f5e83ba",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "Human Prescription Drug Label",
    "name": {
        "text": "Finasteride and Tadalafil"
    },
    "value": "20250324",
    "ingredients": [
        {
            "name": "FINASTERIDE",
            "code": "57GNO57U7G"
        },
        {
            "name": "TADALAFIL",
            "code": "742SXX0ICT"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2"
        },
        {
            "name": "CARRAGEENAN",
            "code": "5C69YCD2YJ"
        },
        {
            "name": "HYPROMELLOSES",
            "code": "3NXW29V3WO"
        },
        {
            "name": "POTASSIUM CHLORIDE",
            "code": "660YQ98I10"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        },
        {
            "name": "SHELLAC",
            "code": "MB5IUD6JUA"
        },
        {
            "name": "ALCOHOL",
            "code": "3K9958V90M"
        },
        {
            "name": "ISOPROPYL ALCOHOL",
            "code": "ND2M416302"
        },
        {
            "name": "BUTYL ALCOHOL",
            "code": "8PJ61P6TS3"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "AMMONIA",
            "code": "5138Q19F1X"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "POTASSIUM HYDROXIDE",
            "code": "WZH3C48M4T"
        }
    ],
    "indications": "finasteride tadalafil indicated initiate treatment signs symptoms benign prostatic hyperplasia ( bph ) men enlarged prostate 26 weeks . limitations finasteride tadalafil recommended 26 weeks incremental benefit tadalafil decreases 4 weeks 26 weeks , incremental benefit beyond 26 weeks unknown [ ( 14 ) ] .",
    "contraindications": "recommended finasteride tadalafil one capsule ( containing finasteride 5 mg tadalafil 5 mg ) orally daily approximately time every day 26 weeks . take finasteride tadalafil empty stomach [ pharmacology ( 12.3 ) ] .",
    "warningsAndPrecautions": "finasteride tadalafil capsule combination finasteride tadalafil . supplied finasteride tadalafil capsules contain finasteride 5 mg tadalafil 5 mg white opaque , size `` 3 `` cellulose capsules , imprinted `` n `` cap `` 652 `` body black ink filled white white powder , free physical defects . finasteride tadalafil capsules supplied follows : bottles polyester coil sealed heat-sealed foil cap 30-count per bottle ( ndc 70954-652-10 ) 90-count per bottle ( ndc 70954-652-20 ) . storage handling store 20° 25°c ( 68° 77°f ) ; excursions permitted 15° 30°c ( 59° 86°f ) [ usp controlled room temperature ] .",
    "adverseReactions": "finasteride tadalafil contraindicated following situations : concomitant form organic nitrate , either regularly and/or intermittently . finasteride tadalafil potentiate hypotensive effect nitrates [ warning ( 5.1 , 5.2 ) ( 7.1 ) ] . patients known hypersensitivity finasteride , tadalafil , components finasteride tadalafil . hypersensitivity included stevens-johnson syndrome , exfoliative dermatitis , pruritis , urticaria , angioedema [ ( 5.8 ) ( 6.2 ) ] . pregnancy [ ( 5.7 ) ( 8.1 ) ] . concomitant guanylate cyclase ( gc ) stimulator . finasteride tadalafil may potentiate hypotensive effects gc stimulators [ ( 7.1 ) ] .",
    "indications_original": "Finasteride and tadalafil is indicated to initiate treatment of the signs and symptoms of benign prostatic hyperplasia (BPH) in men with an enlarged prostate for up to 26 weeks.\n                  \n                  \n                     Limitations of Use\n                  \n                  Finasteride and tadalafil is not recommended for more than 26 weeks because the incremental benefit of tadalafil decreases from 4 weeks until 26 weeks, and the incremental benefit beyond 26 weeks is unknown [see Clinical Studies (14)].",
    "contraindications_original": "The recommended dosage of finasteride and tadalafil is one capsule (containing finasteride 5 mg and tadalafil 5 mg) orally once daily at approximately the same time every day for up to 26 weeks.\n                  \n                  Take finasteride and tadalafil on an empty stomach [see Clinical Pharmacology (12.3)].",
    "warningsAndPrecautions_original": "Finasteride and Tadalafil Capsule is a combination of finasteride and tadalafil.\n                  \n                  \n                     How Supplied \n                  \n                  Finasteride and Tadalafil Capsules contain finasteride 5 mg and tadalafil 5 mg in white opaque, size \"3\" cellulose capsules, imprinted \"N\" on the cap and \"652\" on the body in black ink filled with white to off white powder, free from physical defects.\n                  \n                  Finasteride and Tadalafil Capsules are supplied as follows: bottles with a polyester coil and sealed with a heat-sealed foil cap as 30-count per bottle (NDC 70954-652-10) or 90-count per bottle (NDC 70954-652-20).\n                  \n                  \n                     Storage and Handling \n                  \n                  Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].",
    "adverseReactions_original": "Finasteride and tadalafil is contraindicated in the following situations:\n                  \n                     Concomitant use of any form of organic nitrate, either regularly and/or intermittently. Finasteride and tadalafil can potentiate the hypotensive effect of nitrates [see Warning and Precautions (5.1, 5.2) and Drug Interactions (7.1)].\n                     \n                     Patients with known hypersensitivity to finasteride, tadalafil, or to any of the components of finasteride and tadalafil. Hypersensitivity reactions have included Stevens-Johnson syndrome, exfoliative dermatitis, pruritis, urticaria, and angioedema [see Warnings and Precautions (5.8) and Adverse Reactions (6.2)].\n                     Pregnancy [see Warnings and Precautions (5.7) and Use in Specific Populations (8.1)].\n                     \n                  \n                  \n                     Concomitant use with a guanylate cyclase (GC) stimulator. Finasteride and tadalafil may potentiate the hypotensive effects of GC stimulators [see Drug Interactions (7.1)]."
}